The funding will be employed to expedite ZuriMED’s development and adoption of revolutionary Surgical-Fiberlock technology, designed for minimally invasive soft tissue surgery. ZuriMED aims to broadly leverage its groundbreaking technology to address the growing surgical device market in both the United States and Europe within the next three years. ZuriMED Technologies is an innovation-driven Swiss company based in Zurich that spun off in 2015 from the Institute for Biomechanics at ETH Zurich. ZuriMED excels as an innovation engine, driven by a dynamic management team and backed by a network of world-leading scientists, clinicians, and medical industry experts. The NKF team was led by Corporate/M&A partner Roman Sturzenegger, working with associate Binderiya Gan-Ayush and junior associates Niklaus Hatz and Tristan Bohn (all Corporate/M&A).

---

28th August 2023